Conquer Cancer through AI DISCLAIMER This presentation has been prepared by LunitInc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or warranty express or…
Conquer Cancer
through AI
DISCLAIMER
This presentation has been prepared by LunitInc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or
warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or any opinion contained herein. The
information contained in this presentation should be considered in the context of the circumstances prevailing at the time and will not be updated to reflect material developments that may occur
after the date of the presentation. Neither LunitInc. nor any of its affiliates, officers, directors or advisors shall have any liability whatsoever (in negligence or otherwise) for any loss arising from
any use of this presentation or its contents or otherwise arising in connection with this presentation. This presentation is being communicated only to persons who have professional experience
in matters relating to investments and to persons to whom it may be lawful to communicate it (all such persons being referredtoas “relevant persons”). This presentation is only directed at
relevant persons and any investment or investment activity relating to this presentation is only available to relevant persons or will be engaged in only with relevant persons. Solicitations resulting
from this presentation will only be responded to if the person concerned is a relevant person. Other persons should not rely or act upon this presentation or any of its contents. This presentation
does not constitute or form part of an offer, invitation or recommendation to purchase or subscribe for any securities, and no part of it shall form the basis of or be relied upon in connection with
any contract, commitment or investment decision in relation to any securities. No money, securities or other consideration isbeing solicited, and, if sent in response to this presentation or the
information contained herein, will not be accepted. The presentation may contain statements that reflect LunitInc.’s beliefs and expectations about the future. These forward-looking statements
are based on a number of assumptions about the future, some of which are beyond LunitInc.’s control. Such forward-looking statements are subject to certain risks and uncertainties that could
cause actual results to differ materially from those contemplated by the relevant forward-looking statements. LunitInc. does not undertake any obligation to update any forward-looking
statements to reflect events that occur or circumstances that arise after the date of this presentation. Certain data in thispresentation was obtained from various external data sources, and Lunit
Inc. has not verified such data with independent sources. Accordingly, LunitInc. makes no representations as to the accuracy or completeness of that data, and such data involves risks and
uncertainties and is subject to change based on various factors. You agree to keep the contents of this presentation strictlyconfidential. All or any part of this presentation may not be taken
away, reproduced, redistributed or retransmitted in any manner. By attending this presentation, you are agreeing to be bound by the foregoing limitations.
Since 2013 l 1
st
Generation Medical AI Company l Listed in KOSDAQ since 2022
32026 INVESTOR RELATIONS
About Lunit
Conquer Cancer through AI
Global Investors
Backed by leading global investors
Global Partners
Established partnerships with industry giants
Industry Leader
Best-in-class AI technology and products
Commercial Success
Successfully scaling out revenue growth
Foreign investment
=$73M 60%
· Raised $122M while unlisted
· 12%of global shareholders after IPO
Top 10%of KOSDAQ listed 1,800 companies in Korea
Chosen by
leading bio companies
Chosen by leading
medical device companies
Multiple global pharmas
· Unprecedented “AA-AA” highest level in
technology assessment among healthcare
companies
HQSeoul l NewYorkl Amsterdam
CAGR 173%
(2019-2025)
Unit : $ Million
(1$=1,400₩)
· Best performance proven by direct comparison
with global competitors in various studies
· High revenue growth
with 173% CAGR (2019 -2025)
· Lunit INSIGHT (X-RAY)
First company globally
to exceed $10M in sales
· LunitInternational (former “Volpara”)
revenue consolidation
0.1
1.0
4.7
9.9
17.9
38.7
59.4
32.7
20192020202120222023202420252026
1H
2026 INVESTOR RELATIONS4
Company OverviewLunit INSIGHTLunit SCOPE
Company Overview
Core Competence
Appendix
Global leader in AI technology
Best-in-Class A.I.
•Top-tier proprietary AI technology
•30+ papers presented in top AI conferences
•Large-scale medical data for R&D (N = +4 million cases)
•The only Korean companyspotlighted by World
Economic Forum, CB Insights
2019 / 2020 / 2021
CB Insights
DIGITAL HEALTH 150
International spotlight
Global Recognition
2017
CB Insights
AI 100
#1
Top Ranked in AI Competitions
1 Lunit
2 Harvard Univ
3
1 Lunit
2 IBM
3 Microsoft
1 Microsoft
5 Lunit
7 Google
Tumor Proliferation
Assessment
2015
Main Task
(CLS-LOC)
2016
MICCAI Grand
Challenge
2017
Camelyon
Eindhoven
Univ. of Tech
2020 / 2022 -2025
TECHNOLOGY PIONEER /
GLOBAL INNOVATOR /
ASSOCIATE PARTNER
Publications in Major Peer-
reviewed Journals & Abstracts
590
Research Partnerships
100
Industry leading clinical studies
Medical Expertise
•15+ full-time board-certified physician
•10+ million medical data collected for AI training
•Strong academic validation leading to high credibility
2026 INVESTOR RELATIONS
Conquer Cancer through AI
Cancer
diagnosis
support
solutions
Cancer
treatment
support
solutions
50% more patients can
be screened earlier
50% more patients
can be eligible for
immunotherapy
1
2
DNA / RNA
Increase
Survival of
Cancer Patients
AI research
platform
AI
Increase cancer survival through AI-powered cancer diagnosis and treatment
5
Chest CT
Chest X-RayMammography
3D Mammo
(DBT)
CT / MRI
Tissue
50%
50%
Company Overview
Flagship
Lunit INSIGHT CXR / MMG
Flagship
Lunit SCOPE IO
Company OverviewLunit INSIGHTLunit SCOPEAppendix
2021 INVESTOR RELATIONS
6
2026 INVESTOR RELATIONS
LunitINSIGHT Roadmap
ProductRoadmapBeyond cancer risk prediction to autonomous AI
Current
RiskAssessment
Foundation Model
Autonomous AI
AI-CAD
AI-based Risk PredictionAI CustomizationAutonomous AI in Cancer Screening
X
▪Hybrid AI model combining
EMR datawithsynthetic
mammography(DBT)images
▪Cost efficiency maximized through AI
▪Near-perfect accuracy achievable through
large-scale learning
▪Final clinical decision: AI
Risk Assessment Product
C-CAD
2.23
Lunit AI
0.14
More than 94%
Reduction in FP
marks
More than 50%
reduction in costs
Human
AI
Improve AI accuracy
across all customers
▪Final clinical decision:
physicians
2026 INVESTOR RELATIONS7
▪Periodicupdates of the AI core model
▪AI customization using data provided
from each site
Expected Performance with Autonomous AI
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
International
Higher Reading Accuracy
LunitINSIGHT Value
Lunit INSIGHTLunit SCOPECompany Overview
Better performance than specialists, proven in major studies
Appendix
1
Clinically proven to show excellence in medical image analysis
0.6
ROC AUC (Accuracy)
0.650.70.750.80.850.90.95
의사단독
MMG
Mammography
CXR
Chest X-Ray
2026 INVESTOR RELATIONS8
Lunit INSIGHT CXR
Doctor + Lunit INSIGHT CXR
Doctor Only
Lunit INSIGHT MMG
Doctor + Lunit INSIGHT MMG
Doctor Only
Extensively
validated
through studies
Studies/abstracts
390
EvidencePerformance
ACTA RADIOLOGICA
CXR reference : Ju Gang Nam,"Developmentand Validation of Deep Learning–based Automatic Detection Algorithm for Malignant
Pulmonary Nodules on Chest Radiographs ", Radiology Vol. 290, No. 1(2018):218–228, doi:10.1148/radiol.2018180237
MMG reference : Hyo-Eun Kim, "Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a
retrospective, multireaderstudy", The Lancet Digital HeathVol 2, No. 3(2020):e138-e148, doi:/10.1016/S2589-7500(20)30003-0
2026 INVESTOR RELATIONS9
LunitINSIGHT Value
Large-scale
Prospective
RCT*
Lunit INSIGHT CXR
Lunit INSIGHT MMG
Outcome is measured after the
baseline state of the subjects is
determined and controlled
intervention applied.
Study
designed
ProspectiveRetrospective
Study Method
What is prospective study?
Reliability
Bias
Outcome
Detection rate of
actionable lung
nodules
Detection rate of
malignant lung
nodules
A Group (n=5238)
Radiologist + AI
31
(0.59%)
8
(0.15%)
B Group (n=5238)
Radiologist only
13
(0.25%)
0
(0.0%)
Flagship prospective MMG study
55,579 women
screened for
breast cancer
Study on ‘Double
Reading’ by Karolinska
Institutet(Sweden)
Outcome
Detection rate of
cancer per 1,000
women
Recall rate per
1,000 women
1Radiologist
- LunitINSIGHT MMG
4.328
2Radiologists
4.129.3
LunitINSIGHT MMG
4.115.5
Flagship prospective CXR study
Data
quality
Recall
errors
Higher possibility to
receive reimbursementif
backed by prospective
studies
*Randomized Controlled Trial
: Research method in which subjects are randomly divided into control and experimental groups for comparison
Real World EvidenceBuilding solid evidence through prospective studies
Large-scale
Prospective
Study
10,476 Patients
with chest X-Ray
RCT study on ‘lung
nodule detection rate’
at Seoul National
University Hospital
(Korea)
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
2026 INVESTOR RELATIONS
LunitINSIGHT Business
10
Current Commercialization Status
First AI company collaboration for our x-ray business
—General Manager K
“In Japan especially, many of the elder people cannot move from home to the clinic to take x-ray. Our x-ray with Lunit AI
can visit to take x-ray immediately at home, so it is a significant difference. After we used Lunit AI in the market, I didn’t
have any complaints. From Fujifilm’s standpoint, whatever AI lunit made has a very high quality, so we would want to
implement it in our x-ray system or PACS system.Customers have already started to use AI and expect more support.”
Felt very high customer satisfaction
—Global Marketing Manager M
“This is actually outfirst AI company collaboration for our x-ray business.The offering will be available on all of GE
digital, fixed, and mobile, and even fluoroscopy.Leveraging the long-term established expertise, that GE has on x-ray
equipment in combination with Lunit’s technology will help to keep up with the customer needs, care deeply about patients
and diagnosing physicians or radiologists.”
Lunit has both strong clinical record and national scalability
—Global Software Product Manager P
“Lunit has a strong clinical validation track record and is registered in Europe and alsomore than 19 countries, making
it an excellent partner for developing solutions that bring our customers intelligent and definitive answers to their
daily needs.We believe that the integration of Lunit’s AI in Agfa’s advanced medical imaging workstation will help facilitate
more effective clinical workflows in various hospital situations.”
UsagePartner Testimonials
8,300
Number of paying sites worldwide
1
LunitUsers among
Top 10 Hospitals in Korea
10
- Excludes demo and research use; only commercial sales
- Source: KOSTAT.go.kr Appx. 47M Chest X-ray exams performed annually in Korea
Chest X-Ray exams in Korea
2
Analyzed by LunitINSIGHT CXR 2024
20%
Portion of revenue from
Overseas 1H2026
95%
LunitINSIGHT MMG Users among
47 Large Hospitals in Korea 2025
57%
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
2026 INVESTOR RELATIONS11
LunitCompany A
Company B
AI
Algorithm AAlgorithm B
Sensitivity
81.9%
67.0%67.4%
Accuracy
(ROC AUC)
95.6%92.2%92.0%
Lunit(Partnership Signed)ScreenpointZebra Medical Vision
Salim, et al. JAMA Oncol. 2020 Aug 27.
IF 24.799
1)
GE
Healthcare
Hologic
Others
GMM IMS
Giotto
Siemens
Fujifilm
Care-
strea
m
Canon
Fujifilm
Philips
Others
GE
Healthcare
Siemens
Agfa
Fujifilm
Agfa
Philips
GE
Healthcare
Others
Siemens
Change
IBM
Sectra
Superior Performance
Robust Research (SCIE Journals
2
)Larger Market Access
ResearchPartnershipAccuracy
Key Success Factor: Proven to Be Best-in-Class
LunitINSIGHT Superior Performance
Comparing 3 Commercial Mammography AI
Retrospective analysis of 8 years of mammography screening
Compared AI screening performance with data from 739 breast cancer-
diagnosed women and 112,924 healthy women
- Impact factor, Top 7 among Oncology Journals
Robust research with strong clinical
evidence in peer-reviewed journals
Proven superior performance
compared to competitors
Access to 50% of market share
through global partnership
- SCIE(Science Citation Index Expanded): Citation index originally produced by the
Institute for Scientific Information and created by Eugene Garfield
Global Reading Software (PACS)
Market
Global X-Ray Device
Market
Global Mammography Market
ModalityCompany (Country)
of
Journals
Chest X-Ray
Lunit69
Qure.ai
22
Annalise.ai
10
Oxipit
3
Zebra
0
Others (>10)
None
Mammography
Lunit77
ScreenPoint
45
DeepHealth
3
Zebra
1
Others (>10)
None
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
2026 INVESTOR RELATIONS12
LunitINSIGHT Strategy
Next Step
Becoming global standard of care by B2G expansion and successful reimbursement
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
Selected into Australia’s National
Breast Cancer Screening Program
BSNSW (BreastScreenNew South Wales)
: A free national breast cancer screening program
in NSW (MMG every 2 years to women over 40).
The first case globally in which an AI-based
solution is being applied in a national cancer
screening program.
Possibility of reimbursement in Europe
B to G
Reimbursement
National Cancer Screening Programs
Europe
Korea
AI can reduce burden caused by
Double Reading in Europe
First Case
Expansion
Active Reimbursement in Japan/Korea,
Expanding into Other Markets
Eligible to enter the non-benefit
reimbursement market from
LunitINSIGHT CXR: 2024.03 ~
LunitINSIGHT MMG: 2024.3Q ~
Government Regulation/ Support
DirectSales
Expansion into Direct Sales
DirectSales
Modality VendorsPACSVendors
BM -CAPEX Model
Payment per device
BM -OPEX Model
Payment per image
X
IndirectSales
Outcome
Detection rate
of cancer per
1,000 women
Recall rate per
1,000 women
1 Radiologist
- LunitINSIGHT MMG
4.328
2 Radiologists
4.129.3
LunitINSIGHT MMG4.115.5
15
14
8
3
1
2026.1Q
2025
2024
2023
2022
B2G 사업수주현황(누적)
Australia
Sweden/Saudi Arabia
Portugal/Iceland/Qatar/Singapore/South Korea
AbuDhabi / Italy / Spain / Peru / Egypt / France
· · ·
Malta
2026 INVESTOR RELATIONS13
LunitAcquires LunitInternatioal(former “Volpara”) (May, 2024)
Lunitx LunitInternational
LunitInternational
Breast Products
Density
Breast Risk Assessment
QC
Reporting
•Stable revenue (>$30m in ARR in 2024)
•Large-scale data for training (imaging + clinical data)
•Distribution channel in US for Lunit INSIGHT
•KOL engagement in US for autonomous AI
•Enable business development for lung and other cancer
screening product suites
•Boost AI capabilities to strengthen all products
•Synergy with LunitINSIGHT enables faster market
penetration of LIL products
•Distribution of LIL products in non-US territories
•Enable development of lung cancer and other cancer related
screening
Data
...
AI
Reinforce
Reinforce
Reinforce
Reinforce
Future Direction
Lung cancer screening
XX cancer screening
...
Expand
Data-AI flywheel model
in all cancer screening
40%+ of US
Mammo images
covered
3,600+
Customers
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
Value
Value
2026 INVESTOR RELATIONS14
Strong Revenue Growth Driven by Lunitx LunitInternational Synergy
LunitX LunitInternational
Accelerated and Sustained Revenue Growth in Cancer Diagnostics Expected from Lunitx LunitInternational Synergy
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
Revenue Trend in Cancer Screening
LunitInternational
Acquisition May 2024
Unit : $ Million
(1$=1,400₩)
1H2026
CS Revenue
YoY: ▲20%
CAGR
95%
(2022-2025)
2
2
4
4
2
5
11
32
48
29
7
13
36
52
31
20222023202420252026.1H
Overseas
Korea
Expected Opt-in Rate > 50%
TraditionalBusiness Model
NewBusiness Model
Provider offers SecondReadAI
TM
direct to patients for an out-of-
pocket fee at registration or point of
care.
Revenue per analysis is x10-20
Lunit INSIGHT DBT
Image Interpretation
Lunit INSIGHT DBT
Provider
Provider
$$$
$$$
$
Patient
Patient
Direct to Patient Business Model SecondRead AI Gaining Strong Traction in US Market
2026 INVESTOR RELATIONS
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
15
Lunitx LunitInternational
LunitINSIGHT RiskAssessment Product
16
LunitCancer Screening
Establishing a new standard for early breast cancer detection and personalized preventive care
Before:Risk Assessment Solutions
LunitInternational'RiskPathways'
•A risk assessment software designed to
identify and manage high-risk patients for
breast, lung, colorectal, gastric, and
pancreatic cancer
•Assesses risk based on EMR datasuch as
family history, genetic information, lifestyle,
etc
•Personalized prediction is limited due to
the absence of imaging information
After : Integrated Risk Prediction Solutions
Hybrid AI modelcombining EMR data with synthetic
mammography (DBT) images
Strength: Leverages objective imaging data to provide
more precise and individualized 5-year breast cancer risk
assessments.
LunitINSIGHT Risk Assessment Product
Prognosia
(Imaging data)
Lunit
International
(EMR data)
PrognosiaBusiness Strengths
•FDA(BreakthroughDeviceDesignation): Recognized for technological and clinical value, enabling accelerated market entry
•Optimized for U.S. market: Validated with U.S. SEER-based data and aligned with major guidelines (NCCN, USPSTF, ASCO)
2025.06
Completion of Prognosia
acquisition and product
integration
ProductDevelopmentTimeline
Late 2025
FDA submission
2026
v0.4 FDAApproval
A New Standard
for Personalized
Screening
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
2026 INVESTOR RELATIONS
2027
v1.0 Commerciallaunch
▪Single AI model for all customer
▪AI accuracy varies depending on each customer’s
data and AI training data
Foundation Model
17
LunitCancer Screening
AI v1.0
AI Core Model(v1.0)
AI v1.0
AI v1.0
Current: Unified AI Model
Customer A
AI version 1.0
Accuracy
80%
Customer B
Accuracy
87%
AI version 1.0
Customer C
Accuracy
88%
AI version1.0
AI v1.0
Overcoming Limitations Through AI Customization
AI
Core Model (v1.0)
AI Updates
Periodic Updates of
the AI Core Model
Customer B
Small-scale
Training data
Accuracy
87%
Accuracy
94%
Accuracy
99%
Customer C
Accuracy
88%
Accuracy
95%
Accuracy
99%
Large-scale Data
Data
Data
AI v1.0
AI v1.0
AI v1.0
Periodic
Updates of
the AI Core
Model
Small-scale
Training data
Data
▪Maintain high AI accuracy for each customer
through customized AI models
AI
Core Model (v2.0)
Customer A
Small-scale
Training data
Accracy
80%
Accuracy
92%
Accuracy
99%
v1.1.2 Custom AI
v1.1.1 Custom AI
v1.1 Custom AI
v1.2.2 Custom AI
v1.2.1 Custom AI
v1.2 Custom AI
v1.3.2 Custom AI
v1.3.1 Custom AI
v1.3Custom AI
AI Customization
using small-scale
data provided
from each site
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
2026 INVESTOR RELATIONS
Pre-visitImage AcquisitionInterpretationFollow Up
ScorecardAnalyticsRisk PathwaysLiveLunit INSIGHT
Diagnostic Aid
RadiologyImagesReportBiopsy resultRisk
Cancer CenterHospital
Data-AIFlywheel Ecosystem
Community HospitalLaboratoryHospiceScreening Center
Radiology Imaging
Center
EMR
Customization AI for Autonomous AI Requires Platform Approach of Data-AI Flywheel Ecosystem
LunitCancer Screening
Customers
2026 INVESTOR RELATIONS
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
18
X
Our Future is Autonomous AI
LunitCancer Screening
2026 INVESTOR RELATIONS
Lunit INSIGHTLunit SCOPECompany OverviewAppendix
19
AI customization using data provided from each site
C-CAD
2.23
Lunit AI
0.14
More than94%
reduction in FP marks
More than50%
reduction in costs
Human
AI
Expected Performance with Autonomous AI
A
B
C
Z
Custom AI v1.1 v1.1.1 v1.1.2
ACC 82% 92% 99%
Custom AI v1.2 v1.2.1 v1.2.2
ACC 89% 94% 99%
Custom AI v1.3 v1.3.1 v1.3.2
ACC 92% 95% 99%
Custom AI v1.4 v1.4.1 v1.4.2
ACC 93% 96% 99%
Data for few short learning
Customization
Customization
Customization
Customization
Data for core
model training
AI v1.0
Path to Autonomous AI: Customization of AI Model for Each Customer
Limitation of current AI applications
: Single AI model for all customer
A
B
C
Z
AI v1.0
ACC 80%
AI v1.0
ACC 87%
AI v1.0
ACC 91%
AI v1.0
ACC 92%
AI model
Expected Benefits of Autonomous AI
AI model
Iterative
Self-improvement
Increased
Efficiency
24/7
Availability
No
Human Errors
Personalization
2026 INVESTOR RELATIONS
20
IOuIHC
High Complexity in Cancer
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
21
Even cancers in the same organ have
different biological characteristics and prognoses.
Response
Rate
KEY: Personalized Treatment by Biomarkers
Mutation Type
1,000+
Morphological Type
1,000+
Tumor Heterogeneity
10+
WHO’s Morphological
Classification
Gene Mutations Causing Cancer
10
%
3 months
Survival Period
Traditional: One general treatment for all cancer patients
Biomarker test
X
Patients
Response
Rate
Now & Future: Biomarker-based personalized treatment
Survival Period
30%
50%
60%
40%
30%
24
months
Patients
Biomarker test
Diagnosis and
Treatment
Results
Biopsy
Blood
test
DNA
test
(positive /
negative)
Personalized Approach Is Key to Cancer Treatment
LunitSCOPE Development
Diagnosis and Treatment
2026 INVESTOR RELATIONS
Others
LunitSCOPE: AI-powered Biomarkers for Major Cancer Drugs
LunitSCOPE Development
ImmunotherapyTargeted Small MoleculesADCs, mAbs, BsAbs
Targeted Therapy
Immune Checkpoint Inhibitors
Cancer Vaccines
Adoptive Cell Therapy
Cytokine Therapy
Targeted Small Molecules
Antibody-Drug
Conjugates
Bispecific Abs
Monoclonal Abs
Immunotherapy
Cancer Treatment Landscape
Biomarker Landscape
40%
40%
$67B$57B
$9~10
B
Chemotherapy
Hormone Therapy
...
20%
20242030
Source: Globaldata
268
77
16
15
5
156
469
148
59
54
24
7
176
+10%
CAGR
Global Revenue
for Cancer Drugs ($B)
Immuno-oncology
ADC
Bi-specific
CAR-T
Cancer Vaccine
Other Targeted Therapy
2026 INVESTOR RELATIONS
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
22
LunitSCOPE: AI-powered Biomarkers for Major Cancer Drugs
LunitSCOPE Overview
Purpose
Biomarkers for IO therapeuticsBiomarkers for ADCs therapeuticsScreening for multiple biomarkers
Key Features
Identification of predictive tissue/cell features
(H&E)
Quantification of protein expression
level/pattern (IHC)
End-to-end prediction of specific genomic
mutations
Potential
Applications
CDxbiomarkers for IO drugs
Complimentary biomarkers
CDx biomarkers for ADC drugs
Prescreening genomic mutations
Patient enrollment in clinical trials
Related
Therapies
Immune Checkpoint InhibitorsTargeted therapy -mostly ADCsTargeted therapy -small molecules
2026 INVESTOR RELATIONS
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
23
Monotherapy : 3x more responsive when using Lunit SCOPEIO
24242026 INVESTOR RELATIONS
Global Big Pharma
Currently discussing research agreement/
collaboration with leading global pharmas
GroupNORR
All analyzed set3221.9%
Lunit SCOPE(+)
8
(25%)
62.5%
Lunit SCOPE(-)
24
(75%)
8.3%
Phase 1 :“multiple cancer”, anti-PD-(L)1 Inhibitor
Pharma
Anti-PD-(L)1
Combotherapy: 2x more responsive when using Lunit SCOPE IO
Phase 1/2 : Colorectal cancer (MSS), TGF-beta Inhibitor + anti-PD-(L)1 Inhibitor
Pharma
TGF-beta inhibitor
Pharma
Anti-PD-(L)1
GroupNORR
All analyzed set3112.9%
Lunit SCOPE(+)
16
(51.6%)
25.0%
Lunit SCOPE(-)
15
(48.4%)
0%
Monotherapy : 2.6x more responsive when using Lunit SCOPEIO
GroupNpCR
All analyzed set3828.9%
Lunit SCOPE(+)
8
(21%)
75.0%
Lunit SCOPE(-)
30
(79%)
16.7%
Phase 2 : Rectal cancer, Chemoradiotherapy + anti-PD-(L)1 Inhibitor
Pharma
Anti-PD-(L)1
Combotherapy: 1.6x higher PFS when using Lunit SCOPE IO
Phase 2 : Nasopharyngeal cancer, Chemotherapy + anti-PD-(L)1 Inhibitor
Pharma
Anti-PD-(L)1
Chemotherapy
GroupNPFS rate (%)
All analyzed set2432.2%
Lunit SCOPE(+)
12
(50%)
52.1%
Lunit SCOPE(-)
12
(50%)
0%
+20
Proven to Be Effective in Pharma Clinical Trials
LunitSCOPE & Pharma
Pharma
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
Key Clinical Studies for LunitSCOPE
Lunit SCOPE Value
High Prediction of Response to
Immunotherapy in Lung Cancer
Patient Group
Overall Response Rate
LunitSCOPE IO Positive26.8%
Lunit SCOPE IO Negative11.3%
Patient Group
Overall Response Rate
LunitSCOPE IO Positive22.8%
LunitSCOPE IO Negative3.9%
[PD-L1 1~49% Group] ORR -6 times higher
[Regardless of PD-L1 status]
ORR -2.5 times higher
Expanding LunitSCOPE IO to All Cancer Types
Patient Group
Overall Response Rate
LunitSCOPE IO Positive26.3%
Lunit SCOPE IO Negative15.8%
[All cancer types] ORR -1.7 times higher
uIHCbased AI Quantification
for Various Antibodies Protein Expression Analysis
Staining
(Antibodies)
No. of
Negative
TC /
Positive
TC
Cell detection
performance
(mF1)
TPS
classification
performance
(Accuracy)
TROP2
1243 / 328978.9%94.0%
MET3493 / 113480.5%96.0%
Claudin 18.22927 / 7472.7%94.0%
DLL32973 / 368.9%100%
HER32768 / 13860.9%94.0%
FGFR22358 / 43850.8%81.0%
E-Cadherin443 / 91279.2%90.0%
uIHCbased AI Quantification
Shows Predictive Power in HER2
Group
n
ORR,
N (%)
PFS,
months,
median
(95% CI)
HR
(95% CI)
P
AI-H3-low1101.4 (1.3-NR)Ref
< .001
AI-H3-
high
198 (42.1)4.4 (4.0-12.0)
0.12
(0.04-0.38)
Survival Rate: 3x Gap
Prediction of Various Lung Cancer
Driver Mutations by LunitSCOPE GP
External Validation set
N (%)
AUC
SensitivitySpecificity
EGFR-mt224 (28.3)0.72375.5%52.6%
KRAS-mt130 (16.4)0.72186.2%22.5%
ALK-tr46 (5.8)0.73839.1%81.8%
ROS1-tr62 (7.8)0.60914.5%70.6%
RET-tr11 (1.4)0.68318.2%96.4%
MET-ex12 (1.5)0.84983.3%74.4%
All-WT277 (35.0)N/A15.9%99.2%
EGFR Mutation Subtype Prediction
by LunitSCOPE GP
Sensitivity
E19del(n=495, AUC=0.894)
L858R (n=492, AUC=0.887)
E20ins (n=430, AUC=0.850)
Others(n=436, AUC=0.865)
Comutation(n=448, AUC=0.843)
0.75
0.50
0.25
0.00
1.000.750.500.250.00
Specificity
1.00
Mutation Detection>70-80%
25
2026 INVESTOR RELATIONS
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
Business Model Paired with pharma’s drug, to generatehigh sales by active testing before treatment
Lunit SCOPE BM
Clinical Trial
Patient Triage using
Pay for Drug
$$$$
Cancer Drug
Pay for Test
$$
Hospital
STEP 1
SCOPE Test
STEP 2
If Positive
STEP 3
Prescription
STEP 2
If Negative
Patient
When approved by FDA as CDx, it proceeds to reimbursement 100%
Insurance Company
Patient
STEP 3
Other treatments
Pharma
Lunit
CDx Biomarker
Insurance Company
Drug Development Process
FDA Approval
Drug
Proof of efficacy
CDxproof of efficacy
2026 INVESTOR RELATIONS
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
26
Commercialization Roadmap From Pharma Research to Companion Diagnostics (CDx)
Lunit SCOPE Commercial Strategy
2027~:FDA Approval
Exponential increase in revenue
Approved as CDxproduct;
authorized for reimbursement
LunitSCOPE Market
Research Revenue: Per Analysis Payment from Pharma Partners
CDxApproval ExamplePD-L1
Increase in US Labs that order PD-L1 tests
CDx
Approved
Lab
0
10
20
30
40
50
60
70
80
Year
2015
Hospital
STEP 1
SCOPE Test
STEP 2
If Positive
STEP 2
If Negative
Patien
t
Patient
STEP 3
Other treatments
STEP 3
Prescription
FDA Approval
Drug
Proof of efficacy
CDxproof of efficacy
$10B+
$27B+
Step 3: As a CTAStep 2: Broader Use, RUO ServiceStep 1: Biopharma Engagement
Pilot or Bake-off Study
Active Pharma
Translational Research
10+
Clinical Trial Enrollment
Screening patients with SCOPE for patient
enrollment in clinical trialsORAnalyzing
existing clinical trial data with SCOPE
LunitSCOPE Revenue Trend
(RUO Sales)
Clinical collaborations with big pharma
to generate research revenue
We are
engaged with
15+
$-
$1,000,000
$2,000,000
$3,000,000
$4,000,000
$5,000,000
$6,000,000
$7,000,000
$8,000,000
RUO Revenue
2-3X
Growth
1Merck11Astellas
2BMS12Incyte
3Roche13Takeda
4J&J14Gliead
5AZ15Sanofi
6Novartis16BeiGene
7Pfizer17Daiichi
8Amgen18Bayer
9Eli Lilly19GSK
10Abbvie20Teva
Apply SCOPE in Clinical Trials
CDxSales for Clinical UseRegulatory Approval as CDx
Active Pharma
15+
Global Top20 Pharma of 2024
based on oncology drug revenues
$
$$$
Per Test Payment for Clinical Use
Cancer Biomarker Market
Target Market
2026 INVESTOR RELATIONS
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
27
Strong Traction with Major Industry Vendors for Future Distribution Scalability
Lunit SCOPE Channels
Among Top5 antibody makers,
We are engaged with
Staining Component
Digitization Component
Viewing Component
Antibody Manufacturer
Pathology Labs
Among Top5 Labs,
We are engaged with
-as well as other keyCROs
Among Top5 platforms,
We are engaged with
Most pathology scanners
are compatible with
Lunit’sAI
Scanner ManufacturerPath-PACS Manufacturer
2
5+
2
3
1Labcorp
2Quest
3Sonic
4Neogenomics
5Pathgroup
Top 5 Anatomic Pathology
Labs Based on Revenue
Example companies:
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
28
2026 INVESTOR RELATIONS
Next Steps
Lunit Oncology
Cover All Types of DrugsMulti-omicBiomarkers
Drug Discovery & Development
LunitSCOPE will deliver optimal cancer
treatment through multi-omics analysis
LunitSCOPE biomarkers shall be applied to
drug discovery/development
Comprehensive Data Analysis
LunitSCOPE will be able to cover all
types of oncology drugs
PathomicsRadiomics
Metabolomics
“Multi-omics”
Genomics
Source : Maximize market research PVT. LTD
Second Step
Proteomics
Global Oncology
Drug Market 2029
AppendixLunit INSIGHTCompany OverviewLunit SCOPE
29
Personalized Treatment
전문의진단시
년주기
년주기
현재모두년주기로검진
Precision
Screening
Precision
Treatment
Precision
Diagnostics
Precision
Monitoring
Personalized screening
through Lunit INSIGHT
Lunit-based
Monitoring
Personalized Screening / Diagnosis
Having strong faith that a data-driven approach is the future,
Lunit will be the center of cancer care
Globally become the new standard of care
Conquer Cancer through AI-powered Precision Medicine
Vision
30
Personalized screening
through Lunit INSIGHT
Lunit-based
Monitoring
31
THANK YOU
31
2026 INVESTOR RELATIONS
Consolidated Financial Statements
32
Lunit INSIGHTCompany OverviewLunit SCOPEAppendix
Appendix
Source: DART, Company K-IFRS Audited
Unit:KRW millionUnit:KRW million
1H
2026
202520242023
Current Asset
217,16355,620111,882
230,418
Non CurrentAsset
328,107314,292321,032
37,503
Total Assets
545,271369,912432,914
267,921
Current Liabilities
196,795212,212252,413
12,794
Non CurrentLiabilities
16,83420,26717,767
20,017
Total Liabilities
213,629232,479270,180
32,811
Capital Stock
37,22914,62814,471
14,351
Additional paid-in Capital
746,774549,031526,646
515,518
Others
15,128(121)(278)
182
Retained earnings
(Accumulated Deficit)
(467,489)(426,105)(378,104)
(294,941)
Total shareholders’ equity
331,642137,433162,735
235,110
1H
2026
202520242023
Operating Income
45,76683,129 54,180
25,080
Operating Cost
74,728 166,233 122,127
67,297
Operating Income(Loss)
(28,962)(83,104)(67,947)
(42,217)
Financial Income
14,841 89,254 19,202
10,257
Financial Expenses
26,330 53,050 34,743
4,764
Other Income
38 151 107
80
Other Expenses
62 85 121
119
Income(Loss)
before Tax
(40,476)(46,835)(83,502)
(36,764)
Tax Expenses(Income)
891555(806)
35
Net Income(Loss)
(41,367)(47,390)(82,695)
(36,798)
Source: DART, Company K-IFRS Audited
Statement of Financial PositionIncome Statement